GlassScriptPhysician profile
Lawrence S Rosenthal
NPI 1942359021
$9,514.47
in general payments reported to CMS, 2019-2025
37 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $833 · 2021: $1,318 · 2022: $1,938 · 2023: $1,727 · 2024: $1,767 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,525 · Education: $33.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,524.76 |
| Education | $33.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,747.21 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,737.06 | 2020-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $878.92 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $785.45 | 2020-2025 | Stelara, Simponi Aria, Tremfya |
| Pfizer INC. | $544.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $505.69 | 2019-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $494.28 | 2019-2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $268.64 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $254.91 | 2020-2024 | Linzess |
| Gilead Sciences, INC. | $220.89 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $211.12 | 2019-2025 | Ocaliva |
| Redhill Biopharma INC. | $193.38 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Lilly USA, LLC | $181.71 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $178.79 | 2023-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $169.81 | 2019-2025 | Rebyota |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $165.23 | 2022-2024 | Ibsrela |
| Daiichi Sankyo INC. | $153.84 | 2019-2023 | Injectafer |
| Evoke Pharma, INC. | $146.79 | 2021-2025 | Gimoti |
| Celltrion USA INC. | $120.63 | 2023-2025 | Vegzelma, Yuflyma |
| Phathom Pharmaceuticals, INC. | $72.52 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $70.45 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $47.38 | 2023-2024 | Dupixent |
| Genzyme Corporation | $47.00 | 2024 | |
| Novo Nordisk INC | $36.69 | 2025 | Wegovy |
| Medtronic, INC. | $34.98 | 2021-2024 | Endoflip |
| Ipsen Biopharmaceuticals, INC | $34.54 | 2025 | Iqirvo |
| Vivus LLC | $29.46 | 2024 | Pancreaze |
| Organon LLC | $27.97 | 2023-2024 | Renflexis |
| Qol Medical, LLC | $27.68 | 2021 | |
| Ucb, INC. | $27.22 | 2019 | |
| Pentax of America, INC. | $18.31 | 2025 | Pentax Medical, C2 Cryoballoon Focal Controller, C2 Cryoballoon |
| Fresenius Kabi USA, LLC | $16.31 | 2024 | Idacio |
| Neurocrine Biosciences, INC. | $16.25 | 2024 | Ingrezza |
| Olympus America INC. | $15.74 | 2019 | |
| Allergan, INC. | $13.70 | 2019 | |
| W. L. Gore & Associates, INC. | $11.95 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $7.74 | 2023 | Blueboost |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Rosenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.